Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MorphoSys has submitted a clinical trial application to initiate a Phase I trial using the HuCAL-derived antibody MOR103 for the treatment of rheumatoid arthritis.
Subscribe to our email newsletter
MorphoSys plans to reveal the target molecule of its lead antibody program MOR103 and additional information on the design of the Phase I clinical study on January 16, 2008.
Marlies Sproll, chief scientific officer of MorphoSys, said: “The initiation of clinical development of our lead proprietary drug candidate MOR103 is a significant milestone for MorphoSys and we achieved it as planned by the end of 2007.”